FY2025 EPS Estimate for Xenon Pharmaceuticals Cut by Analyst

Key Points

• Cantor Fitzgerald has decreased its FY2025 earnings per share (EPS) estimate for Xenon Pharmaceuticals from ($3.43) to ($3.85), while the consensus estimate is currently ($3.10) per share.
• Xenon Pharmaceuticals reported earnings of (1.07) per share for the latest quarter, missing the consensus estimate by $(0.04).
• Despite recent downgrades in price targets by various analysts, the stock retains a consensus rating of "Moderate Buy" with an average target price of $53.20.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for shares of Xenon Pharmaceuticals in a research note issued on Tuesday, August 12th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the biopharmaceutical company will post earnings per share of ($3.85) for the year, down from their prior estimate of ($3.43). The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share. Cantor Fitzgerald also issued estimates for Xenon Pharmaceuticals' FY2026 earnings at ($4.08) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.03) by ($0.04). During the same period in the prior year, the company posted ($0.75) EPS.

A number of other research analysts have also issued reports on the stock. Chardan Capital reissued a "buy" rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday, August 12th. HC Wainwright reissued a "buy" rating and set a $53.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday, May 13th. Wells Fargo & Company reduced their target price on shares of Xenon Pharmaceuticals from $50.00 to $47.00 and set an "overweight" rating for the company in a research note on Tuesday, May 13th. William Blair reissued an "outperform" rating on shares of Xenon Pharmaceuticals in a research note on Monday, May 5th. Finally, Wedbush boosted their target price on shares of Xenon Pharmaceuticals from $42.00 to $43.00 and gave the company an "outperform" rating in a research note on Tuesday, August 12th. Eleven research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Xenon Pharmaceuticals presently has an average rating of "Buy" and an average target price of $53.20.

Xenon Pharmaceuticals Trading Down 0.7%

NASDAQ:XENE traded down $0.2550 during mid-day trading on Thursday, hitting $37.5650. The stock had a trading volume of 250,125 shares, compared to its average volume of 897,058. The company has a 50 day simple moving average of $32.72 and a 200-day simple moving average of $33.96. The stock has a market capitalization of $2.90 billion, a price-to-earnings ratio of -10.58 and a beta of 1.16. Xenon Pharmaceuticals has a 52 week low of $26.74 and a 52 week high of $46.00.

Institutional Trading of Xenon Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. L1 Capital Pty Ltd bought a new stake in shares of Xenon Pharmaceuticals in the 2nd quarter worth approximately $41,000. Tower Research Capital LLC TRC raised its holdings in shares of Xenon Pharmaceuticals by 10,614.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,357 shares of the biopharmaceutical company's stock worth $168,000 after purchasing an additional 5,307 shares in the last quarter. Soleus Capital Management L.P. bought a new stake in shares of Xenon Pharmaceuticals in the 2nd quarter worth approximately $2,466,000. Vestal Point Capital LP raised its holdings in shares of Xenon Pharmaceuticals by 53.8% in the 2nd quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company's stock worth $62,600,000 after purchasing an additional 700,000 shares in the last quarter. Finally, Oxford Asset Management LLP raised its holdings in shares of Xenon Pharmaceuticals by 242.4% in the 2nd quarter. Oxford Asset Management LLP now owns 21,138 shares of the biopharmaceutical company's stock worth $662,000 after purchasing an additional 14,964 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.